Bausch Health Companies Inc. (BHC) – Concerns over Xifaxan generics

Bausch Health Companies Inc. (BHC) (Q1FY23)

Introduction

Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States.

The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceutical products.

Highlights

Bausch Health suffered a significant loss following the announcement of the tentative approval by the FDA for the abbreviated new drug application submitted by Norwich Pharmaceuticals for the medication Xifaxan, used in the treatment of irritable bowel syndrome. This indicates that generic competition for Xifaxan is imminent, which is expected to have a considerable impact on the drugmaker’s sales and revenues for this particular medication.

Stock Report

Bausch Health Inc’s stock price showed a volatile trend in past 3-months period. It declined by 17.4% during the period. The stock price declined by 20.89% in past 1-year. The stock has a 52-week high of $10.23 and its 52-week low is $4.

In the past 3 years, the stock has declined by 65.29%. BHC has a 50- day moving Avg. and 200-day moving Avg. of $7.37 and $7.36, respectively.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 36

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates